246 related articles for article (PubMed ID: 34208778)
1. Inhibition of Ceramide Synthesis Reduces α-Synuclein Proteinopathy in a Cellular Model of Parkinson's Disease.
Mingione A; Pivari F; Plotegher N; Dei Cas M; Zulueta A; Bocci T; Trinchera M; Albi E; Maglione V; Caretti A; Bubacco L; Paroni R; Bottai D; Ghidoni R; Signorelli P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208778
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.
Mingione A; Dei Cas M; Bonezzi F; Caretti A; Piccoli M; Anastasia L; Ghidoni R; Paroni R; Signorelli P
Cell Physiol Biochem; 2020 Jan; 54(1):110-125. PubMed ID: 31999897
[TBL] [Abstract][Full Text] [Related]
3. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson's Disease Targeting Neuroinflammation.
Chen CM; Yen CY; Chen WL; Lin CH; Wu YR; Chang KH; Lee-Chen GJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494411
[TBL] [Abstract][Full Text] [Related]
4. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
5. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
7. Autophagy activation promotes clearance of α-synuclein inclusions in fibril-seeded human neural cells.
Gao J; Perera G; Bhadbhade M; Halliday GM; Dzamko N
J Biol Chem; 2019 Sep; 294(39):14241-14256. PubMed ID: 31375560
[TBL] [Abstract][Full Text] [Related]
8. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease.
Engelender S
Autophagy; 2008 Apr; 4(3):372-4. PubMed ID: 18216494
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Spiro AS; Furuta A; Cooper A; Garner B; Kabuta T; Halliday GM
Mov Disord; 2015 Oct; 30(12):1639-47. PubMed ID: 25594542
[TBL] [Abstract][Full Text] [Related]
11. Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.
Grassi D; Howard S; Zhou M; Diaz-Perez N; Urban NT; Guerrero-Given D; Kamasawa N; Volpicelli-Daley LA; LoGrasso P; Lasmézas CI
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2634-E2643. PubMed ID: 29487216
[TBL] [Abstract][Full Text] [Related]
12. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy.
Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG
Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813
[TBL] [Abstract][Full Text] [Related]
14. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
[TBL] [Abstract][Full Text] [Related]
15. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
[TBL] [Abstract][Full Text] [Related]
16. Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease.
Guo M; Wang J; Zhao Y; Feng Y; Han S; Dong Q; Cui M; Tieu K
Brain; 2020 May; 143(5):1476-1497. PubMed ID: 32355963
[TBL] [Abstract][Full Text] [Related]
17. Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to α-Synuclein Gain.
Lin G; Lee PT; Chen K; Mao D; Tan KL; Zuo Z; Lin WW; Wang L; Bellen HJ
Cell Metab; 2018 Oct; 28(4):605-618.e6. PubMed ID: 29909971
[TBL] [Abstract][Full Text] [Related]
18. Lipid levels correlate with neuronal and dopaminergic markers during the differentiation of SH-SY5Y cells.
Marlet FR; Muñoz SS; Sotiraki N; Eliasen JN; Woessmann J; Weicher J; Dreier JE; Schoof EM; Kohlmeier KA; Maeda K; Galvagnion C
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167212. PubMed ID: 38750771
[TBL] [Abstract][Full Text] [Related]
19. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
20. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
